Targeting survivin in cancer therapy

Pre-clinical studies

Marzia Pennati, Marco Folini, Nadia Zaffaroni

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Survivin is a structurally unique member of the inhibitor of apoptosis protein family that in addition to acting as a suppressor of programmed cell death also plays a central role in cell division. Owing to its massive up-regulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a promising target for new anticancer interventions. Several preclinical studies have demonstrated that down-regulation of survivin expression or function, accomplished by means of various strategies (including the use of antisense oligonucleotides, small interfering RNAs, ribozymes, dominant negative mutants and small molecule antagonists), reduced tumor growth potential, increased the apoptotic rate, and sensitized tumor cells to chemotherapeutic drugs and ionizing radiation in different human tumor preclinical models. Moreover, the first survivin inhibitors have already reached the clinic with some promise. However, due to its documented role in some normal tissues, the possibility that survivin disruption could affect normal cell function, mainly the hematopoietic and immune systems, cannot be excluded. In this context, a better understanding of the effects exerted by survivin on normal versus malignant cells will be important for the design of optimal strategies to selectively disrupt survivin in cancer.

Original languageEnglish
Title of host publicationApoptosome: An Up-and-coming Therapeutical Tool
PublisherSpringer Netherlands
Pages147-168
Number of pages22
ISBN (Print)9789048134151, 9789048134144
DOIs
Publication statusPublished - 2010

Fingerprint

Neoplasms
Therapeutics
Inhibitor of Apoptosis Proteins
Hematopoietic System
Catalytic RNA
Antisense Oligonucleotides
Ionizing Radiation
Cell Division
Small Interfering RNA
Clinical Studies
Immune System
Cell Death
Up-Regulation
Down-Regulation
Growth
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Cell cycle
  • Human cancers
  • Inhibitors of apoptosis-proteins
  • Survivin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pennati, M., Folini, M., & Zaffaroni, N. (2010). Targeting survivin in cancer therapy: Pre-clinical studies. In Apoptosome: An Up-and-coming Therapeutical Tool (pp. 147-168). Springer Netherlands. https://doi.org/10.1007/978-90-481-3415-1-8

Targeting survivin in cancer therapy : Pre-clinical studies. / Pennati, Marzia; Folini, Marco; Zaffaroni, Nadia.

Apoptosome: An Up-and-coming Therapeutical Tool. Springer Netherlands, 2010. p. 147-168.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pennati, M, Folini, M & Zaffaroni, N 2010, Targeting survivin in cancer therapy: Pre-clinical studies. in Apoptosome: An Up-and-coming Therapeutical Tool. Springer Netherlands, pp. 147-168. https://doi.org/10.1007/978-90-481-3415-1-8
Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: Pre-clinical studies. In Apoptosome: An Up-and-coming Therapeutical Tool. Springer Netherlands. 2010. p. 147-168 https://doi.org/10.1007/978-90-481-3415-1-8
Pennati, Marzia ; Folini, Marco ; Zaffaroni, Nadia. / Targeting survivin in cancer therapy : Pre-clinical studies. Apoptosome: An Up-and-coming Therapeutical Tool. Springer Netherlands, 2010. pp. 147-168
@inbook{6fcc96353712406098519b168f79d359,
title = "Targeting survivin in cancer therapy: Pre-clinical studies",
abstract = "Survivin is a structurally unique member of the inhibitor of apoptosis protein family that in addition to acting as a suppressor of programmed cell death also plays a central role in cell division. Owing to its massive up-regulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a promising target for new anticancer interventions. Several preclinical studies have demonstrated that down-regulation of survivin expression or function, accomplished by means of various strategies (including the use of antisense oligonucleotides, small interfering RNAs, ribozymes, dominant negative mutants and small molecule antagonists), reduced tumor growth potential, increased the apoptotic rate, and sensitized tumor cells to chemotherapeutic drugs and ionizing radiation in different human tumor preclinical models. Moreover, the first survivin inhibitors have already reached the clinic with some promise. However, due to its documented role in some normal tissues, the possibility that survivin disruption could affect normal cell function, mainly the hematopoietic and immune systems, cannot be excluded. In this context, a better understanding of the effects exerted by survivin on normal versus malignant cells will be important for the design of optimal strategies to selectively disrupt survivin in cancer.",
keywords = "Apoptosis, Cell cycle, Human cancers, Inhibitors of apoptosis-proteins, Survivin",
author = "Marzia Pennati and Marco Folini and Nadia Zaffaroni",
year = "2010",
doi = "10.1007/978-90-481-3415-1-8",
language = "English",
isbn = "9789048134151",
pages = "147--168",
booktitle = "Apoptosome: An Up-and-coming Therapeutical Tool",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Targeting survivin in cancer therapy

T2 - Pre-clinical studies

AU - Pennati, Marzia

AU - Folini, Marco

AU - Zaffaroni, Nadia

PY - 2010

Y1 - 2010

N2 - Survivin is a structurally unique member of the inhibitor of apoptosis protein family that in addition to acting as a suppressor of programmed cell death also plays a central role in cell division. Owing to its massive up-regulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a promising target for new anticancer interventions. Several preclinical studies have demonstrated that down-regulation of survivin expression or function, accomplished by means of various strategies (including the use of antisense oligonucleotides, small interfering RNAs, ribozymes, dominant negative mutants and small molecule antagonists), reduced tumor growth potential, increased the apoptotic rate, and sensitized tumor cells to chemotherapeutic drugs and ionizing radiation in different human tumor preclinical models. Moreover, the first survivin inhibitors have already reached the clinic with some promise. However, due to its documented role in some normal tissues, the possibility that survivin disruption could affect normal cell function, mainly the hematopoietic and immune systems, cannot be excluded. In this context, a better understanding of the effects exerted by survivin on normal versus malignant cells will be important for the design of optimal strategies to selectively disrupt survivin in cancer.

AB - Survivin is a structurally unique member of the inhibitor of apoptosis protein family that in addition to acting as a suppressor of programmed cell death also plays a central role in cell division. Owing to its massive up-regulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a promising target for new anticancer interventions. Several preclinical studies have demonstrated that down-regulation of survivin expression or function, accomplished by means of various strategies (including the use of antisense oligonucleotides, small interfering RNAs, ribozymes, dominant negative mutants and small molecule antagonists), reduced tumor growth potential, increased the apoptotic rate, and sensitized tumor cells to chemotherapeutic drugs and ionizing radiation in different human tumor preclinical models. Moreover, the first survivin inhibitors have already reached the clinic with some promise. However, due to its documented role in some normal tissues, the possibility that survivin disruption could affect normal cell function, mainly the hematopoietic and immune systems, cannot be excluded. In this context, a better understanding of the effects exerted by survivin on normal versus malignant cells will be important for the design of optimal strategies to selectively disrupt survivin in cancer.

KW - Apoptosis

KW - Cell cycle

KW - Human cancers

KW - Inhibitors of apoptosis-proteins

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=80052476181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052476181&partnerID=8YFLogxK

U2 - 10.1007/978-90-481-3415-1-8

DO - 10.1007/978-90-481-3415-1-8

M3 - Chapter

SN - 9789048134151

SN - 9789048134144

SP - 147

EP - 168

BT - Apoptosome: An Up-and-coming Therapeutical Tool

PB - Springer Netherlands

ER -